JGC
VRTX icon

J. Goldman & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

J. Goldman & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,700
Closed -$771K – 903
2025
Q4 		$771K Buy
+1,700
New +$733K 0.02% 419
2023
Q3 		– Sell
-17,500
Closed -$6.16M – 494
2023
Q2 		$6.16M Buy
+17,500
New +$5.9M 0.22% 111

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

J. Goldman & Co's VRTX Position: Q3 2025 in Review

J. Goldman & Co sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 1,045 shares — an estimated $465K sold.

J. Goldman & Co first reported a position in VRTX in Q2 2017 and held it in 8 quarters. The position peaked at $8.71M in Q4 2022. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • J. Goldman & Co reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • J. Goldman & Co sold 1,045 Vertex Pharmaceuticals shares in Q3 2025, an estimated $465K.
  • J. Goldman & Co first reported a position in Vertex Pharmaceuticals in Q2 2017 and held it in 8 quarters.
  • J. Goldman & Co's Vertex Pharmaceuticals position peaked at $8.71M in Q4 2022.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.